Press Releases

July 18, 2017 – Silk Road Medical Announces $47 Million Financing led by Norwest Venture Partners and Funds Managed by Janus Capital Management LLC

SUNNYVALE, Calif.,July 18, 2017 /PRNewswire/ — Silk Road Medical, Inc., Financing to Support Rapid Growth of TransCarotid Artery Revascularization (TCAR) Procedure More…

December 12, 2016 – Updated Clinical Data on TCAR Presented at the 44th Annual
VEITH Symposium

SUNNYVALE, Calif.,Dec. 12, 2016 /PRNewswire/ — Silk Road Medical, Inc., Presentations from the ROADSTER 1 and ROADSTER 2 Studies Highlight the Excellent Procedural Outcomes and Long Term Durability of TransCarotid Artery Revascularization More…

September 15, 2016 – New Medicare Coverage Option for TransCarotid Artery Revascularization (TCAR) Procedures

SUNNYVALE, Calif.,Sept. 15, 2016 /PRNewswire/ — Silk Road Medical, Inc., a company dedicated to surgical and endovascular innovation to prevent the devastating burden of stroke, announced the Centers for Medicare and Medicaid Services (CMS) has extended coverage for the TransCarotid Artery Revascularization (TCAR) procedure under the existing National Coverage Determination 20.7. More…

June 15, 2016 – Updated Clinical Data on TCAR Presented at the 2016 Society for Vascular Surgery Annual Meeting

SUNNYVALE, Calif., June 15, 2016 /PRNewswire/ — Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced that the 2016 Vascular Annual Meeting of the Society for Vascular Surgery (SVS) held June 8-11 in National Harbor, MD featured six presentations on the company’s ENROUTE® Transcarotid Neuroprotection and Stent System, the first and only products specifically designed and indicated for TransCarotid Artery Revascularization (TCAR). More…

April 13, 2016 – FDA 510(k) Clearance and First Patients Treated in the US with the Next Generation ENROUTE® Transcarotid Neuroprotection System

SUNNYVALE, Calif., April 13, 2016 /PRNewswire/ — Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced that the United States Food and Drug Administration (US FDA) has granted 510(k) clearance for its next generation ENROUTE Transcarotid Neuroprotection System (NPS). More…

March 15, 2016 – CE Mark Approval and First Patients Treated with the Next Generation ENROUTE® Transcarotid Neuroprotection System

SUNNYVALE, Calif., March 15, 2016  – Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced CE Mark approval for its next generation ENROUTE Transcarotid Neuroprotection System (NPS).  The ENROUTE NPS remains the only device specifically designed and indicated for TransCarotid Artery Revascularization (TCAR), a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. More…

November 2, 2015 – First Patient Successfully Enrolled into ROADSTER 2 Transcarotid Artery Revascularization (TCAR) Study

SUNNYVALE, Calif., Nov. 2, 2015 /PRNewswire/ – Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced the first patient was enrolled in the US ROADSTER 2 post approval study by Vascular Specialists at Greenville Memorial Hospital in Greenville, South Carolina. More…

October 20, 2015 – $57 Million in New Funding for Novel Approach to Preventing Strokes

SUNNYVALE, Calif., Oct. 20, 2015 /PRNewswire/ — Silk Road Medical, Inc., a company dedicated to alleviating the devastating burden of stroke through surgical innovation, today announced it has received up to $57 million in equity and debt funding from new and existing investors. More…

October 6, 2015 – First U.S. Commercial Case with the ENROUTE® Transcarotid Stent System

SUNNYVALE, Calif., Oct. 6, 2015 /PRNewswire/ — Silk Road Medical, Inc. announced the first U.S. commercial case using the ENROUTE Transcarotid Stent System was successfully performed at Kaiser Permanente Moanalua Medical Center in Honolulu, HI, by Vascular Surgeon Peter A. Schneider, M.D.  The ENROUTE Transcarotid Stent is the first and only carotid stent designed specifically for a new procedure called TransCarotid Artery Revascularization, or TCAR. More…

May 28, 2015 – Silk Road Medical Appoints Andrew Davis as Executive Vice President of
Global Sales

SUNNYVALE, Calif., May 28, 2015 /PRNewswire/ — Silk Road Medical, Inc., a pioneer in the development of transcarotid therapies for intra and extracranial vascular diseases, announces the appointment of Andrew (Andy) Davis to the position of Executive Vice President of Global Sales. More…

May 19, 2015 – FDA Grants Premarket Approval for Silk Road Medical’s ENROUTE® Transcarotid Stent System

SUNNYVALE, Calif., May 19, 2015 — Silk Road Medical, Inc., a pioneer in the development of transcarotid therapies for intra and extracranial vascular diseases, announces the company has received Premarket Approval (PMA) from the United States Food & Drug Administration (FDA) for the ENROUTE Transcarotid Stent System. The ENROUTE Transcarotid Stent is the first carotid stent that is introduced and implanted into the carotid artery through a direct common carotid access point to enable a safe and more direct approach to carotid artery stenting. More…

April 17, 2015 – First U.S. Commercial Procedure with the ENROUTE® Transcarotid Neuroprotection System

SUNNYVALE, California, April 17, 2015 – Silk Road Medical, Inc. announced the first U.S. commercial procedure using the ENROUTE Transcarotid Neuroprotection System (NPS) was successfully performed at Mills-Peninsula Medical Center in Burlingame, CA by Vascular Surgeon John E. Rosenman, M.D., F.A.C.S. More…

February 10, 2015 – FDA 510(k) Clearance of the ENROUTE® Transcarotid
Neuroprotection System

SUNNYVALE, Calif., Feb. 10, 2015 /PRNewswire/ — Silk Road Medical, Inc., a pioneer in the development of transcarotid therapies for intra and extracranial vascular diseases, announces the company has received Food & Drug Administration (FDA) 510(k) clearance for its ENROUTE Transcarotid Neuroprotection System (NPS).  The ENROUTE Transcarotid NPS is a first in class system used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while performing carotid angioplasty and stenting (CAS). More…

November 24, 2014 – Silk Road Medical Unveils Unprecedented Pivotal Data From The ROADSTER Trial

SUNNYVALE, Calif., Nov. 24, 2014 /PRNewswire/ — Silk Road Medical, Inc. announced the 30 day outcomes from the ROADSTER IDE Study were presented this month at the Late Breaking Clinical Trials Session at the 2014 Vascular InterVentional Advances (VIVA) Meeting in Las Vegas, with additional data presented at the VEITH Symposium in New York, NY.  The trial studied the ENROUTE™ Transcarotid Neuroprotection System (NPS) (Silk Road Medical, Inc., Sunnyvale, CA), which is designed to provide direct access to the carotid artery and reduce the risk of stroke during carotid angioplasty and stenting (CAS) by diverting dangerous debris away from the brain with a surgically-inspired mechanism to temporarily reverse blood flow.  The 1.4% 30 day stroke rate was the lowest seen to date of any contemporary prospective trial of CAS. More…

July 23, 2014 – Silk Road Medical Appoints Ground Breaking Innovator as Chief
Technology officer

SUNNYVALE, Calif., July 23, 2014 /PRNewswire/ — Silk Road Medical, Inc., a developer of advanced devices for the transcarotid treatment of intra- and extra-cranial cerebrovascular disease, announced today the appointment of Michael P. Wallace to the position of Chief Technology officer.  In this new role, Michael will lead the company’s Research and Development efforts across its family of transcarotid access and treatment devices. More…

July 16, 2014 – Silk Road Medical Completes Enrollment In The ROADSTER Clinical Trial For Carotid Artery Disease

SUNNYVALE, Calif., July 16, 2014 /PRNewswire/ — Silk Road Medical, Inc. announced today the completion of enrollment in its pivotal ROADSTER study. The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally invasive procedure.  The device under study is the Company’s ENROUTE™ Transcarotid Neuroprotection System (NPS) which incorporates proven surgical principles to protect the brain from a stroke during carotid angioplasty and stenting, and features a mechanism to divert dangerous debris away from the brain by temporarily reversing blood flow. More…

January 13, 2014 – Silk Road Medical Appoints World Renowned Physician as
Chief Medical officer

SUNNYVALE, Ca., Jan. 13, 2014 /PRNewswire/ — Silk Road Medical, Inc., a developer of advanced devices for the treatment of Carotid Artery disease, announced today the appointment of Sumaira  Macdonald, MD, PhD to the position of Chief Medical officer effective immediately. In this new role, Dr. Macdonald will direct the company’s scientific and technical agenda and lead research in ground breaking endovascular interventions for the prevention and treatment of stroke. More…

  • ©2017 Silk Road Medical

  • 735 North Pastoria Avenue,
    Sunnyvale, CA 94085

    phone: 855.410.TCAR (8227)
    local phone: 408.720.9002
    fax: 408.720.9013